659 related articles for article (PubMed ID: 17129175)
1. Immunobiology of allogeneic hematopoietic stem cell transplantation.
Welniak LA; Blazar BR; Murphy WJ
Annu Rev Immunol; 2007; 25():139-70. PubMed ID: 17129175
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?
Har-Noy M; Slavin S
Med Hypotheses; 2008; 70(6):1186-92. PubMed ID: 18054441
[TBL] [Abstract][Full Text] [Related]
4. Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome.
Hashimoto D; Merad M
Semin Immunol; 2011 Feb; 23(1):50-7. PubMed ID: 21316261
[TBL] [Abstract][Full Text] [Related]
5. Cytolytic pathways in haematopoietic stem-cell transplantation.
van den Brink MR; Burakoff SJ
Nat Rev Immunol; 2002 Apr; 2(4):273-81. PubMed ID: 12001998
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation.
D'Aveni M; Notarantonio AB; Bertrand A; Boulangé L; Pochon C; Rubio MT
Front Immunol; 2020; 11():989. PubMed ID: 32528476
[TBL] [Abstract][Full Text] [Related]
7. Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.
Espinoza-Delgado I; Childs RW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):865-75. PubMed ID: 15485320
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.
Stelljes M; Strothotte R; Pauels HG; Poremba C; Milse M; Specht C; Albring J; Bisping G; Scheffold C; Kammertoens T; Oelmann E; Silling G; Berdel WE; Kienast J
Blood; 2004 Aug; 104(4):1210-6. PubMed ID: 15090450
[TBL] [Abstract][Full Text] [Related]
9. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J
Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406
[TBL] [Abstract][Full Text] [Related]
10. Recombinant IL-7/HGFβ hybrid cytokine separates acute graft-versus-host-disease from graft-versus-tumour activity by altering donor T cell trafficking.
Hu R; Liu Y; Song Y; Su M; Lu X; Rood D; Lai L
Br J Haematol; 2016 Nov; 175(3):505-516. PubMed ID: 27447780
[TBL] [Abstract][Full Text] [Related]
11. [Hematopoietic stem cell transplantation: is it an immunologic therapy?].
Olaya Vargas A; Pérez Gonzáles O
Rev Alerg Mex; 2003; 50(5):192-7. PubMed ID: 14631591
[TBL] [Abstract][Full Text] [Related]
12. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.
Rezvani AR; Storb RF
J Autoimmun; 2008 May; 30(3):172-9. PubMed ID: 18242060
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects.
Bouchlaka MN; Redelman D; Murphy WJ
Immunotherapy; 2010 May; 2(3):399-418. PubMed ID: 20635904
[TBL] [Abstract][Full Text] [Related]
14. Haematopoietic cell transplantation as immunotherapy.
Appelbaum FR
Nature; 2001 May; 411(6835):385-9. PubMed ID: 11357147
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
Du W; Cao X
Front Immunol; 2018; 9():2979. PubMed ID: 30631325
[TBL] [Abstract][Full Text] [Related]
16. A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease.
Ding X; Bian G; Leigh ND; Qiu J; McCarthy PL; Liu H; Aygun-Sunar S; Burdelya LG; Gudkov AV; Cao X
J Immunol; 2012 Nov; 189(10):4719-27. PubMed ID: 23045613
[TBL] [Abstract][Full Text] [Related]
17. Will post-transplantation cell therapies for pediatric patients become standard of care?
Lankester AC; Locatelli F; Bader P; Rettinger E; Egeler M; Katewa S; Pulsipher MA; Nierkens S; Schultz K; Handgretinger R; Grupp SA; Boelens JJ; Bollard CM;
Biol Blood Marrow Transplant; 2015 Mar; 21(3):402-11. PubMed ID: 25064748
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
19. [Allogeneic haematopoietic stem cell transplantation - an overview].
Holtick U; Chemnitz JM; Hallek M; Scheid C
Klin Monbl Augenheilkd; 2015 May; 232(5):641-6. PubMed ID: 25989032
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic approaches to improve graft-versus-tumor effect and reduce graft-versus-host disease.
Tsirigotis P; Or R; Resnick IB; Shapira MY
Immunotherapy; 2012 Apr; 4(4):407-24. PubMed ID: 22512635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
